My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Agenus Inc. - Common Stock
(NQ:
AGEN
)
3.950
-0.040 (-1.00%)
Streaming Delayed Price
Updated: 10:41 AM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
245,364
Open
4.000
Bid (Size)
3.950 (3)
Ask (Size)
3.970 (6)
Prev. Close
3.990
Today's Range
3.900 - 4.100
52wk Range
1.380 - 7.340
Shares Outstanding
348,875,959
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
Today 8:00 EDT
From
Agenus Inc.
Via
Business Wire
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
October 16, 2025
From
Agenus Inc.
Via
Business Wire
Performance
YTD
+27.8%
+27.8%
1 Month
-11.6%
-11.6%
3 Month
-41.2%
-41.2%
6 Month
+89.9%
+89.9%
1 Year
-15.6%
-15.6%
More News
Read More
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
September 09, 2025
From
Agenus Inc.
Via
Business Wire
Examining the Future: Agenus's Earnings Outlook
August 08, 2025
Via
Benzinga
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 05, 2025
From
Agenus, Inc.
Via
Business Wire
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
August 26, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
August 19, 2025
From
Agenus Inc.
Via
Business Wire
Monday's pre-market session: top gainers and losers
August 11, 2025
Via
Chartmill
Agenus Posts 48% Q2 Revenue Miss
August 11, 2025
Via
The Motley Fool
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
August 11, 2025
From
Agenus Inc.
Via
Business Wire
Earnings Scheduled For August 11, 2025
August 11, 2025
Via
Benzinga
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
July 31, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
July 25, 2025
From
Agenus Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
July 07, 2025
Via
Benzinga
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
July 07, 2025
From
Agenus Inc.
Via
Business Wire
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
June 17, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
June 10, 2025
From
Agenus Inc.
Via
Business Wire
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
June 04, 2025
Via
Benzinga
Agenus Stock Is Trading Higher Tuesday: What's Going On?
June 03, 2025
Via
Benzinga
Tuesday's pre-market session: top gainers and losers
June 03, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 03, 2025
Via
Benzinga
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
June 03, 2025
From
Agenus Inc.
Via
Business Wire
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
June 03, 2025
Via
Benzinga
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
May 30, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
May 15, 2025
From
Agenus Inc.
Via
Business Wire
Frequently Asked Questions
Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 3.950
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 10/17/25 10:41 AM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 1.38B
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.